Literature DB >> 25309617

Strategies to eliminate HBV infection.

Rama Kapoor1, Shyam Kottilil2.   

Abstract

Chronic HBV infection is a major public health concern affecting over 240 million people worldwide. Although suppression of HBV replication is achieved in the majority of patients with currently available newer antivirals, discontinuation of therapy prior to hepatitis B surface antigen loss or seroconversion is associated with relapse of HBV in the majority of cases. Thus, new therapeutic modalities are needed to achieve eradication of the virus from chronically infected patients in the absence of therapy. The basis of HBV persistence includes viral and host factors. Here, we review novel strategies to achieve sustained cure or elimination of HBV. The novel approaches include targeting the viral and or host factors required for viral persistence, and novel immune-based therapies, including therapeutic vaccines.

Entities:  

Keywords:  HBV; IL-21; IL-7; PD-1; PD-L1; RNAi; Toll-like receptor; covalently closed circular DNA; cure; elimination; eradication; host; immunity; receptor; seroconvesrion; therapeutic vaccination; treatment; vaccines; viral entry; virus

Year:  2014        PMID: 25309617      PMCID: PMC4190097          DOI: 10.2217/fvl.14.36

Source DB:  PubMed          Journal:  Future Virol        ISSN: 1746-0794            Impact factor:   1.831


  174 in total

Review 1.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

Review 2.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver.

Authors:  Holly Maier; Masanori Isogawa; Gordon J Freeman; Francis V Chisari
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

Review 4.  Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.

Authors:  Mehmood H Hashmi; Peter J Van Veldhuizen
Journal:  Expert Opin Biol Ther       Date:  2010-05       Impact factor: 4.388

5.  Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

Authors:  Ting-Tsung Chang; Yun-Fan Liaw; Shun-Sheng Wu; Eugene Schiff; Kwang-Hyub Han; Ching-Lung Lai; Rifaat Safadi; Samuel S Lee; Waldemar Halota; Zachary Goodman; Yun-Chan Chi; Hui Zhang; Robert Hindes; Uchenna Iloeje; Suzanne Beebe; Bruce Kreter
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

6.  Large surface proteins of hepatitis B virus containing the pre-s sequence.

Authors:  K H Heermann; U Goldmann; W Schwartz; T Seyffarth; H Baumgarten; W H Gerlich
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

7.  A common HLA-DPA1 variant is a major determinant of hepatitis B virus clearance in Han Chinese.

Authors:  Ping An; Cheryl Winkler; Li Guan; Stephen J O'Brien; Zheng Zeng
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

8.  Influence of HLA class II molecules on the outcome of hepatitis B virus infection in population of Zhejiang Province in China.

Authors:  Xue-Qin Meng; Hu-Guang Chen; Yi-Lin Ma; Ke-Zhou Liu
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2003-05

9.  Mucosal immunogenicity of the hepatitis B core antigen.

Authors:  Y Lobaina; D García; N Abreu; V Muzio; J C Aguilar
Journal:  Biochem Biophys Res Commun       Date:  2003-01-17       Impact factor: 3.575

10.  Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection.

Authors:  Jia Liu; Ejuan Zhang; Zhiyong Ma; Weimin Wu; Anna Kosinska; Xiaoyong Zhang; Inga Möller; Pia Seiz; Dieter Glebe; Baoju Wang; Dongliang Yang; Mengji Lu; Michael Roggendorf
Journal:  PLoS Pathog       Date:  2014-01-02       Impact factor: 6.823

View more
  19 in total

Review 1.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

Review 2.  Treatment of hepatitis B virus: an update.

Authors:  Haley Ward; Lydia Tang; Bhawna Poonia; Shyam Kottilil
Journal:  Future Microbiol       Date:  2016-11-18       Impact factor: 3.165

Review 3.  Therapeutic cancer vaccines.

Authors:  Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

Review 4.  Novel tumour antigens and the development of optimal vaccine design.

Authors:  Victoria A Brentville; Suha Atabani; Katherine Cook; Lindy G Durrant
Journal:  Ther Adv Vaccines Immunother       Date:  2018-04-10

5.  Intrahepatic Expression of C-C Motif ligand 5 in Patients with Chronic Hepatitis B.

Authors:  Xiang-An Zhao; Jian Wang; Haiyan Chang; Yong Liu; Yuxin Chen; Guangmei Chen; Rui Huang; Chao Wu
Journal:  Turk J Gastroenterol       Date:  2021-01       Impact factor: 1.852

6.  Natural Killer p46 Controls Hepatitis B Virus Replication and Modulates Liver Inflammation.

Authors:  Wanyu Li; Yanfang Jiang; Xiaomei Wang; Jinglan Jin; Yue Qi; Xiumei Chi; Hong Zhang; Xiangwei Feng; Junqi Niu
Journal:  PLoS One       Date:  2015-08-20       Impact factor: 3.240

Review 7.  Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes.

Authors:  Bradford S Powell; Alexander K Andrianov; Peter C Fusco
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30

Review 8.  Towards the elimination and eradication of hepatitis B.

Authors:  Geoffrey Dusheiko
Journal:  J Virus Erad       Date:  2015-01-01

9.  CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.

Authors:  Madina Karimova; Niklas Beschorner; Werner Dammermann; Jan Chemnitz; Daniela Indenbirken; Jan-Hendrik Bockmann; Adam Grundhoff; Stefan Lüth; Frank Buchholz; Julian Schulze zur Wiesch; Joachim Hauber
Journal:  Sci Rep       Date:  2015-09-03       Impact factor: 4.379

Review 10.  Anti-HBV Drugs: Progress, Unmet Needs, and New Hope.

Authors:  Lei Kang; Jiaqian Pan; Jiaofen Wu; Jiali Hu; Qian Sun; Jing Tang
Journal:  Viruses       Date:  2015-09-15       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.